7 results about "Epidemic strain" patented technology

The application discloses a novel trimeric recombinant protein vaccine. Specifically disclosed are a mutant protein RBD8M with an amino acid sequence of SEQ ID No. 1 and a fusion protein of positions 26-277, positions 1-277 and SEQ ID No. 4. The application also discloses a vaccine containing the fusion protein, and further develops a trimeric recombinant protein vaccine containing the fusion protein and a double adjuvant. Experiments show that the vaccine prepared in the application can effectively induce cellular immunity and humoral immunity of the body in animals, a trace amount of the protein can stimulate a very high immune response of mice, has a good protection effect, can simultaneously produce high-titer neutralizing antibodies against various epidemic strains of the novel coronavirus, is a broad-spectrum effective new coronavirus vaccine, and has important significance for preventing novel coronavirus infection and a wide clinical application prospect.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The application provides a primer probe combination for identifying the genotype of African swine fever virus, comprising a primer probe combination a for identifying a B646L gene, a primer probe combination b for identifying an MGF-110-5L gene and a primer probe combination c for identifying an I177L gene. The method for identifying the genotype of African swine fever virus by using the primer probe combination is as follows: extracting the genomic DNA of a sample to be detected, using the extracted genomic DNA of the sample to be detected as a template, performing a triple fluorescent quantitative PCR reaction by using the primer probe combination, and judging the genotype of African swine fever virus according to the fluorescent signal. The application also provides the application of the primer probe combination to the preparation of a kit for identifying the genotype of African swine fever virus. The concentration and reaction conditions of the primer probe combination are optimized, so that the designed primer probe combination has strong specificity, sensitivity and repeatability, not only solves the identification problem of African swine fever virus, but also simultaneously realizes the synchronous identification of three kinds of epidemic strain genotypes.

The application discloses a general trimeric recombinant protein vaccine for preventing novel coronavirus infection. Specifically disclosed are a mutant protein RBD4M with an amino acid sequence of SEQ ID No. 1 and a fusion protein of positions 26-277, positions 1-277 and SEQ ID No. 4. The application also discloses a vaccine containing the fusion protein, and further develops a trimeric recombinant protein vaccine containing the fusion protein and a double adjuvant. Experiments show that the vaccine prepared in the application can effectively induce cellular immunity and humoral immunity of the body in animals, a trace amount of the protein can stimulate a very high immune response of mice, has a good protective effect, can produce high-titer neutralizing antibodies against various epidemic strains of the novel coronavirus, is a broad-spectrum effective novel coronavirus vaccine, and has important significance for preventing novel coronavirus infection and a wide clinical application prospect.

Provided are a polio vaccine and a method for preparing same. Immunization with vaccines made from poliovirus-like particles can induce high levels of neutralizing antibodies against poliovirus types I, II, and III, exhibiting broad-spectrum neutralizing activity against widely prevalent strains at present. The recombinant polio vaccine does not rely on live viruses. There are no live viruses involved in the vaccine production and testing processes, posing no biosafety risks or risks of inducing OPV vaccine-derived conditions. Also, the vaccine requires no high-grade facilities needed for the production and testing of IPV vaccines, which reduces the costs of production and quality control and improves the accessibility of the vaccine in mid- and low-income countries.

This invention relates to the field of biotechnology, and particularly to primers and methods for whole-genome sequencing of African swine fever virus (ASFV) based on next-generation sequencing platforms and targeted enrichment. This invention discloses a primer set and method for whole-genome sequencing of ASFV based on next-generation sequencing platforms and targeted enrichment, comprising 32 pairs of specific targeted amplification primers. These primers exhibit high specificity and sensitivity, fully leveraging the advantages of next-generation sequencing—high throughput, low cost, high accuracy, and mature technology—to accurately and completely obtain the entire ASFV genome sequence. This invention can obtain complete genetic information of ASFV, identify and diagnose infections of different ASFV genotypes, and, by analyzing the genetic differences among different strains, determine the geographical origin and transmission dynamics of circulating strains, tracing the evolution of recombinant strains. It provides resources for basic research on virus-host interactions and drug resistance, and offers a theoretical basis for developing long-term prevention and control strategies. It also promotes innovation in diagnostic methods.

The application relates to a quadruple fluorescent quantitative PCR detection kit for detecting African swine fever virus (ASFV) type I, type II wild strains and / or ASFV-G-DI177L strains, which comprises a set of specific primers and fluorescent probes for detecting the African swine fever virus type I, type II wild strains and / or ASFV-G-DI177L strains, the nucleotide sequence of the specific primers is shown in SEQ ID NO. 1, 2, 4, 5, 7, 8, 10 and 11; and the nucleotide sequence of the specific fluorescent probes is shown in SEQ ID NO. 3, 6, 9 and 12. The application designs a quadruple fluorescent quantitative PCR detection method, four genes can be detected at the same time, and the four pairs of primers and probes have relatively consistent amplification efficiency. The application establishes a method for identifying the African swine fever virus gene type I wild strain, the gene type II wild strain and the ASFV-G-DI177L strain based on the characteristics of domestic African swine fever epidemic strains.